AstraZeneca's Brilinta wins in diabetic artery disease patients - FiercePharma

AstraZeneca's Brilinta wins in diabetic artery disease patients  FiercePharma

AstraZeneca's Brilinta has a checkered history when it comes to racking up data in new patient pools. But the drug has emerged victorious from its latest test.



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more